Tamoxifen
SIAL/85256 - analytical standard
Synonym: (Z)
CAS Number: 10540-29-1
Empirical Formula (Hill Notation): C26H29NO
Molecular Weight: 371.51
EC Number: 234-118-0
MDL Number: MFCD00010454
Linear Formula: C6H5C(C2H5)=C(C6H5)C6H4OCH2CH2N(CH3)2
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: 85256-50MG
| application(s) | forensics and toxicology pharmaceutical (small molecule) |
| assay | ≥98.0% (HPLC) |
| format | neat |
| grade | analytical standard |
| impurities | ≤0.5% water |
| InChI | 1S/C26H29NO/c1-4-25(21-11 |
| InChI key | NKANXQFJJICGDU-QPLCGJKRSA |
| mp | 97-98 °C (lit.) |
| Quality Level | 100  |
| shelf life | limited shelf life, expiry date on the label |
| SMILES string | CCC(c1ccccc1)=C(/c2ccccc |
| storage temp. | 2-8°C |
| technique(s) | gas chromatography (GC): suitable |
| HPLC: suitable |
| Application: | Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support. |
| Biochem/physiol Actions: | Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells. |
| Symbol |   GHS08,GHS09 |
| Signal word | Danger |
| Hazard statements | H350 - H360 - H410 |
| Precautionary statements | P201 - P273 - P308 + P313 |
| Hazard Codes | T |
| Risk Statements | 45-60-61-64 |
| Safety Statements | 53-45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98.0% (HPLC) |
| mp | 97-98 °C (lit.) |
| Storage Temp. | 2-8°C |
| UNSPSC | 41116107 |